Calyx Acquired by CapVest/GLO Healthcare
The financial transaction details pertaining to the eClinical technology provider's deal were not disclosed.
GLO Healthcare, a healthcare platform created by private equity investor CapVest Partners LLP, has completed the acquisition of Calyx, an software and services provider of medical imaging, IRT, CTMS, RIM and EDC for the clinical trials industry. The terms of the transaction are not being disclosed. Calyx will join GLO’s development and delivery of diagnostic testing for major cancers and other diseases.
Read more about the acquisition.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
